Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia

Official Title

Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia

Summary:

The current understanding of acute myeloid leukemia (AML) is that one site of bone marrow (BM) sampling serves as a window that represents all AML cells distributed throughout the BM, an assumption that has yet to be questioned. Simulation in mice led to inconsistent representation of the full BM, which can incorrectly suggest the absence of leukemic cells. Positron-emission tomography (PET) scan can detect areas of high metabolic activity in the body using for instance a radioactive sugar. In one report, its use in human AML has provided proof-of-principle evidence of unequal distribution of AML cells in BM. Accordingly, the alternative hypothesis is to test if PET scan can demonstrate if BM geography can alter AML cells spread and home them as distinct areas rather than uniform spread as if they are distributed in liquid state.

Trial Description

Primary Outcome:

  • Number of patients with heterogeneous (positron-emission tomography) PET/CT activity before induction chemotherapy
Secondary Outcome:
  • Number of patients with residual (positron-emission tomography) PET/CT activity following induction chemotherapy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society